SaLuDo trial: what clinicians have said so far
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
- NCT06088290 ↗
- Active, not recruiting
- PharmaMar
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on SaLuDo (lurbinectedin in first-line metastatic leiomyosarcoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SaLuDo so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Leiomyosarcoma
- Interventions
- Lurbinectedin; Doxorubicin
- Arms
- Doxorubicin (Dose A) + Lurbinectedin (Dose B) · Experimental
- Doxorubicin (Dose C) + Lurbinectedin (Dose D) · Experimental
- Doxorubicin (Dose E) · Active comparator
- Enrollment
- 469
- Primary outcomes
- PFS by IRC
- Sponsor
- PharmaMar
- Start
- Sep 21, 2023
- Primary completion
- Aug 30, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06088290 · updated Jun 18, 2026
Publications
linked from the registry- Cote GM, Chawla SP, Demetri G, Kasper B, Jones RL, Broto JM, Wooley J, Weiss MC, Tafuto S, Badalamenti G, Carrasco I, Peinado P, Blay JY, Boggio G, Fernandez C, Nieto A, Kahatt C, Alfaro V, Le Cesne A. SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncol. 2025 Apr;21(8):943-951. doi: 10.1080/14796694.2025.2463798. Epub 2025 Feb 11. PubMed 39932221